Gilead Trial Pause Adds To Merck & Co’s HIV Concerns

Might Be End Of Partnership

 
• By Andrew McConaghie
  
Gilead_USA
Gilead is closing in on approval for its long-acting HIV therapy, but the future of its combination with Merck's drug is now uncertain • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anti-infective

More from Therapeutic Category